Author

Marie‐Laure Casadebaig

Observed names: M. Casadebaig, Marie-Laure Casadebaig

Observed institutions: Mayo Clinic, Bristol-Myers Squibb (United States), Celgene (Switzerland), Bristol-Myers Squibb (Switzerland)

OpenAlex ID: A5008943992

Estimands for overall survival in clinical trials with treatment switching in oncology

2021 · Juliane Manitz, Natalia Kan‐Dobrosky, et al. · Pharmaceutical Statistics · 33

KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma

2020 · Saad Z. Usmani, Jesus G. Berdeja, et al. · Blood · 21

Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

2024 · Laurie H. Sehn, Stefano Luminari, et al. · Blood · 19

Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial

2021 · Grzegorz S. Nowakowski, Wolfgang Willenbacher, et al. · International Journal of Hematology · 18

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

2019 · Carla Casulo, Armando Santoro, et al. · Blood · 18

Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study

2019 · Catherine Thieblemont, Susannah Howlett, et al. · British Journal of Haematology · 18

Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).

2019 · Warren P. Mason, Santosh Kesari, et al. · Journal of Clinical Oncology · 10

Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL.

2019 · Grzegorz S. Nowakowski, Wolfgang Willenbacher, et al. · Journal of Clinical Oncology · 10

Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial

2022 · Carla Casulo, Armando Santoro, et al. · Cancer Reports · 9

Safety and Efficacy of the Pd‐l1 Inhibitor Durvalumab With R‐chop or R2‐chop in Subjects With Previously Untreated, High‐risk Dlbcl

2019 · G. Nowakowski, W. Willenbacher, et al. · Hematological Oncology · 7

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐ MIND Study

2026 · Koji Izutsu, Noriko Fukuhara, et al. · Cancer Science · 1

Works count: 11

Citation count: 164

H-index: 9

I10-index: 8